Literature DB >> 23180660

The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta-analysis study.

Francesca Lantieri1, Francesco Caroli, Isabella Ceccherini, Paola Griseri.   

Abstract

Medullary thyroid carcinoma (MTC) is a rare tumor, partially explained by mutations in the rearranged during transfection (RET) proto-oncogene. The nonsynonymous RET polymorphism G691S has been reported as associated with MTC, but findings are discordant. We sought to clarify the role of G691S in MTCs through in silico analysis, genetic association in our patients and a meta-analysis with extensive literature revision. Ninety-three Italian patients were compared to 85 healthy individuals. Results were included in a meta-analysis together with 11 case-control association studies identified through PubMed, EMBASE and Web of Science, with a combined sample of 968 cases and 2,115 controls. No association of G691S with MTC was found in our sample; however, we observed an excess of homozygotes for the variant, significantly higher among females. The overall allelic association in the meta-analysis was significant under the fixed-effect model (odds ratio [OR] = 1.22 [95% confidence intervals: 1.06-1.39], p = 0.0049), but borderline under the random effect model (OR = 1.21 [0.99-1.46], p = 0.0575), with a moderate/high heterogeneity (I(2) = 44.6%, p = 0.047). Under the recessive model of transmission, applied to the eight studies with available genotype frequencies, results were significant under both effect models (OR = 2.016 and OR = 2.022, p = 0.0004). No heterogeneity was anymore detectable. In silico analyses on G691S confirmed a change of the phosphorylation pattern that might account for the enhanced signaling transduction previously reported for G691S in several cancers, thus also explaining its overrepresentation in MTCs. The G691S variant allele does increase the risk for MTC, with a recessive mechanism of action, apparently more evident among females.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180660     DOI: 10.1002/ijc.27967

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

Review 1.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.

Authors:  Xiao-Ping Qi; Rong-Xin Zhang; Jin-Lin Cao; Zhen-Guang Chen; Hang-Yang Jin; Ren-Rong Yang
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

Review 3.  Molecular genetics of thyroid cancer.

Authors:  Maha Rebaї; Ahmed Rebaї
Journal:  Genet Res (Camb)       Date:  2016-05-13       Impact factor: 1.588

4.  Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.

Authors:  Nadiya Sosonkina; Seung-Keun Hong; Dmytro Starenki; Jong-In Park
Journal:  Genes Genomics       Date:  2014-12       Impact factor: 1.839

5.  Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.

Authors:  M N Basaran; M M Tuna; E Karakılıç; B A Doğan; N N İmga; D Berker; S Güler
Journal:  J Endocrinol Invest       Date:  2014-12-12       Impact factor: 4.256

6.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.

Authors:  Miguel Quintela-Fandino; Maria J Bueno; Luis Lombardia; Marta Gil; Antonio Gonzalez-Martin; Raul Marquez; Raquel Bratos; Juan Guerra; Eugene Tan; Antonio Lopez; Ramon Colomer; Ramon Salazar
Journal:  Mol Oncol       Date:  2014-07-17       Impact factor: 6.603

8.  Association of RET genetic polymorphisms and haplotypes with papillary thyroid carcinoma in the Portuguese population: a case-control study.

Authors:  Marina Santos; Teresa Azevedo; Teresa Martins; Fernando J Rodrigues; Manuel C Lemos
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

9.  Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.

Authors:  Vasudha Mishra; Pradnya Kowtal; Pallavi Rane; Rajiv Sarin
Journal:  Cancer Med       Date:  2019-08-13       Impact factor: 4.452

10.  Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

Authors:  Elizabeth Fox; Brigitte C Widemann; Meredith K Chuk; Leigh Marcus; Alberta Aikin; Patricia O Whitcomb; Maria J Merino; Maya Lodish; Eva Dombi; Seth M Steinberg; Samuel A Wells; Frank M Balis
Journal:  Clin Cancer Res       Date:  2013-06-13       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.